anti mouse cd8α antibody Search Results


anti mouse cd8α antibody  (MedChemExpress)
94
MedChemExpress anti mouse cd8α antibody
Inhibition of NAT10 enhances the efficacy of anti–PD-L1 therapy in vivo . A Schematic diagram of the tumor model and treatment schedule with anti-PD-L1 administration. B–D Representative images ( B ), tumor growth curves ( C ), and tumor weights ( D ) of mouse 4T1 tumors from shNC, shNAT10, anti-PD-L1, or the combination of shNAT10 and anti-PD-L1 ( n = 6). E-F Representative mIF images of mouse tumor tissues showing staining for T cells ( E ), Tregs ( F ), and MDSCs ( F ) (scale bar, 20 μm). G - H ELISA analysis of GzmB (G) and IFN-γ (H) levels in the serum of mice from different groups. I Representative IHC staining of PD-L1, CD8, and GzmB in breast cancer tissues ( n = 220), with statistical analysis of staining intensity (scale bar, 200 μm). J Correlation of PD-L1 and CD8, and PD-L1 and GzmB protein levels in breast cancer tissues ( n = 220) assessed by IHC. All data are presented as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001
Anti Mouse Cd8α Antibody, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+mouse+cd8%CE%B1+antibody/Anti-Mouse+CD8%CE%B1+Antibody/pmc12870259-145-10-15
Average 94 stars, based on 1 article reviews
anti mouse cd8α antibody - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
anti-mouse cd8α antibody  (TargetMol)
N/A
   Buy from Supplier
mouse cd8 alpha biotinylated antibody  (Bio-Techne corporation)
90
Bio-Techne corporation mouse cd8 alpha biotinylated antibody
Inhibition of NAT10 enhances the efficacy of anti–PD-L1 therapy in vivo . A Schematic diagram of the tumor model and treatment schedule with anti-PD-L1 administration. B–D Representative images ( B ), tumor growth curves ( C ), and tumor weights ( D ) of mouse 4T1 tumors from shNC, shNAT10, anti-PD-L1, or the combination of shNAT10 and anti-PD-L1 ( n = 6). E-F Representative mIF images of mouse tumor tissues showing staining for T cells ( E ), Tregs ( F ), and MDSCs ( F ) (scale bar, 20 μm). G - H ELISA analysis of GzmB (G) and IFN-γ (H) levels in the serum of mice from different groups. I Representative IHC staining of PD-L1, CD8, and GzmB in breast cancer tissues ( n = 220), with statistical analysis of staining intensity (scale bar, 200 μm). J Correlation of PD-L1 and CD8, and PD-L1 and GzmB protein levels in breast cancer tissues ( n = 220) assessed by IHC. All data are presented as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001
Mouse Cd8 Alpha Biotinylated Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+mouse+cd8%CE%B1+antibody/Mouse+CD8+alpha+Biotinylated+Antibody/bio-techne+corporation___bam116
Average 90 stars, based on 1 article reviews
mouse cd8 alpha biotinylated antibody - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
anti-mouse cd8α antibody  (MedChemExpress)
N/A
Anti-Mouse CD8α Antibody (YTS169.4) is an IgG2 monoclonal antibody targeting mouse CD8α. Anti-Mouse CD8α Antibody (YTS169.4) rapidly depletes or downregulates CD8+ T cells in the spleens of Biozzi AB/H mice. Anti-Mouse CD8α Antibody (YTS169.4) is
   Buy from Supplier

Image Search Results


Inhibition of NAT10 enhances the efficacy of anti–PD-L1 therapy in vivo . A Schematic diagram of the tumor model and treatment schedule with anti-PD-L1 administration. B–D Representative images ( B ), tumor growth curves ( C ), and tumor weights ( D ) of mouse 4T1 tumors from shNC, shNAT10, anti-PD-L1, or the combination of shNAT10 and anti-PD-L1 ( n = 6). E-F Representative mIF images of mouse tumor tissues showing staining for T cells ( E ), Tregs ( F ), and MDSCs ( F ) (scale bar, 20 μm). G - H ELISA analysis of GzmB (G) and IFN-γ (H) levels in the serum of mice from different groups. I Representative IHC staining of PD-L1, CD8, and GzmB in breast cancer tissues ( n = 220), with statistical analysis of staining intensity (scale bar, 200 μm). J Correlation of PD-L1 and CD8, and PD-L1 and GzmB protein levels in breast cancer tissues ( n = 220) assessed by IHC. All data are presented as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: Targeting the NAT10-HDAC4 positive feedback loop counteracts immunosuppression in breast cancer

doi: 10.1186/s13046-025-03638-7

Figure Lengend Snippet: Inhibition of NAT10 enhances the efficacy of anti–PD-L1 therapy in vivo . A Schematic diagram of the tumor model and treatment schedule with anti-PD-L1 administration. B–D Representative images ( B ), tumor growth curves ( C ), and tumor weights ( D ) of mouse 4T1 tumors from shNC, shNAT10, anti-PD-L1, or the combination of shNAT10 and anti-PD-L1 ( n = 6). E-F Representative mIF images of mouse tumor tissues showing staining for T cells ( E ), Tregs ( F ), and MDSCs ( F ) (scale bar, 20 μm). G - H ELISA analysis of GzmB (G) and IFN-γ (H) levels in the serum of mice from different groups. I Representative IHC staining of PD-L1, CD8, and GzmB in breast cancer tissues ( n = 220), with statistical analysis of staining intensity (scale bar, 200 μm). J Correlation of PD-L1 and CD8, and PD-L1 and GzmB protein levels in breast cancer tissues ( n = 220) assessed by IHC. All data are presented as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

Article Snippet: In the CD8+ T cell depletion assay, mice were administered anti-Mouse CD8α antibody (Clone 2.43) (MedChemExpress, #HY-P990790, China) intraperitoneally at a dose of 300 μg daily for three consecutive days.

Techniques: Inhibition, In Vivo, Staining, Enzyme-linked Immunosorbent Assay, Immunohistochemistry